Extended Data Fig. 8: Flow cytometry analysis of anti-TIGIT activity in tumour myeloid cells of E0771 model, and T cells of CT26 model.
From: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
a, Mean fluorescence intensity (MFI) of cell surface MHC-II on tumour-infiltrating dendritic cells (DC, left), macrophages (middle), and monocytes (right), normalized to their respective median MFI value following control treatment. Far right, histogram of representative surface MHC-II expression on tumour monocytes following various treatments. E0771-bearing C57BL/6 J mice were treated as indicated and data were collected at day 7 after treatment. Data are a composite of two independent experiments with n = 4 mice in each group; shown are mean +/− SEM with one-way ANOVA with Dunnett’s multiple comparisons, with the Control IgG group designated as the control group. b, Frequencies of tumour-infiltrating FoxP3- non-Treg CD4 + T cells (left), FoxP3+ Treg CD4 + T cells (middle), and CD8 + T cells (right) out of total CD45+ cells. c, Ratio of tumour CD8 + T cells to FoxP3+ Treg CD4 + T cells. d, e, Additional data related to Fig. 5e,f. Frequencies of TCF1 + TIM3+ memory-like T cells (d) and TOX+ terminally differentiated effector T cells (e) in CT26-tumour bearing mice treated with control and anti-PD-L1 plus anti-TIGIT mIgG2a-LALAPG or mIgG2a antibodies. b-e, Intratumoural CD45+ cells were analysed by flow cytometry at day 3 after treatment (b, c) and gp70 tetramer positive T cells at day 7 after treatment (d, e). Data are representative of one (b, c) or two (d, e) independent experiments with n = 5 mice in each group. b-e, Data in the dot plots are mean +/− SEM with one-way ANOVA with Dunnett’s multiple comparisons, with the anti-PD-L1 monotherapy group designated as the control group.